Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2019

View Archived Issues

"Membrane-anchored molecular adjuvant" improves rabies vaccine

Sorting chimeras from fata morganas

'Deep cultivation' used to describe 79 previously uncharacterized planctomycetal strains

Roche initiates first-in-human study of RO-7247669

KM Biologics presents dengue vaccine tested in monkeys

OBI Pharma opens enrollment in phase I/II study of OBI-999 in advanced solid tumors

DP-13 begins phase II trial in primary aldosteronism

New analgesic target and lead compound identified in rodents

TIFA as a new predictive biomarker of PAH

G. mellonella as a promising in vivo model for assessing the pathogenesis of GBS

Roche presents phase III data for atezolizumab plus bevacizumab in HCC

KY-1043 demonstrates potent antitumor activity in vitro and in vivo

Enrollment ongoing in phase II study of ciprofloxacin/celecoxib fixed-dose combination

First-in-human study of 89Zr-DFO-REGN-3504 for imaging PD-L1 tumors

Prestige Biopharma initiates phase III study of proposed biosimilar HD-204

Array BioPharma, Mirati Therapeutics describe new G12C-mutant GTPase KRAS inhibitors

Incyte patents PD-1/PD-L1 interaction inhibitors

New anticancer compounds discovered at Zymeworks

Bionomics presents Nav1.7 channel blockers

Gilead Sciences is enrolling participants in phase II study of GS-4875

NMPA approves flumatinib mesylate for the treatment of Ph+ chronic myeloid leukemia

GSK-3527497, a new preclinical candidate for effective inhibition of TRPV4

The enteropeptidase inhibitor SCO-792 enters phase II development

PEG12KL4: a new RNA pulmonary delivery vector with confirmed in vivo transfection efficiency

FUEL trial shows effects of udenafil on exercise in single ventricle heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...